Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
245 EUR | -0.08% | -2.62% | +15.68% |
06:14pm | Swiss Market Index Rises; Roche Shines on Promising Weight-loss Drug | MT |
05:16pm | Global markets live: Cisco, EasyJet, Roche, Netflix, Amazon... |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- This company will be of major interest to investors in search of a high dividend stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- With an enterprise value anticipated at 3.25 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.68% | 203B | - | ||
+32.95% | 709B | C+ | ||
+30.77% | 595B | B | ||
-1.89% | 367B | C+ | ||
+20.14% | 334B | B- | ||
+5.79% | 289B | C+ | ||
+14.77% | 239B | B+ | ||
+9.13% | 211B | B- | ||
+8.95% | 171B | C+ | ||
+0.26% | 163B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ROG Stock
- RHO Stock
- Ratings Roche Holding AG